Novel cell-permeable acyloxymethylketone inhibitors of asparaginyl endopeptidase

Biological Chemistry

Volumn 384, Issue 8, 2003, Pages 1239-1246

  Loak, Kylie ^a   Li, Dongtao Ni ^b   Manoury, Bénédicte ^b   Billson, Jeremy ^a   Morton, Fraser ^a   Hewitt, Ellen ^a   Watts, Colin ^b  

^a MEDIVIR AB   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Antigen processing; Asparaginyl endopeptidase; Inhibitor

Indexed keywords

2,2 DIMETHYLPROPIONIC ACID 3 BENZYLOXYCARBONYLAMINO 4 CARBAMOYL 2 OXO BUTYL ESTER; 2,6 DIMETHYLBENZOIC ACID 3 BENZYLOXYCARBONYLAMINO 4 CARBAMOYL 2 OXO BUTYL ESTER; ACYLOXYMETHYLKETONE DERIVATIVE; ASPARAGINYL ENDOPEPTIDASE INHIBITOR; BENZOIC ACID 3 BENZYLOXYCARBONYLAMINO 4 CARBAMOYL 2 OXO BUTYL ESTER; CASPASE 10; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; CATHEPSIN B; CATHEPSIN H; CATHEPSIN L; CATHEPSIN S; CYSTATIN C; CYSTEINE PROTEINASE; EPITOPE; INTERLEUKIN 1BETA CONVERTING ENZYME; LEGUMAIN; LEUPEPTIN; MV 026629; MV 026630; MV 026632; MYELIN BASIC PROTEIN; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPTIDE HYDROLASE INHIBITOR; PROTEINASE INHIBITOR; TETANUS TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; B-LYMPHOCYTES; BENZOIC ACIDS; CATALYSIS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CYSTEINE PROTEINASE INHIBITORS; HUMANS; KINETICS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; T-LYMPHOCYTES;

ANIMALIA; KOBUS; MAMMALIA;

EID: 0141626757     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2003.136     Document Type: Article

References (25)

1. Alvarez-Fernandez, M., Barrett, A.J., Gerhartz, B., Dando, P.M., Ni, J. and Abrahamson, M. (1999). Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J. Biol. Chem. 272, 19195-19203.
2. Antoniou, A.N., Blackwood, S.L., Mazzeo, D. and Watts, C. (2000). Control of antigen presentation by a single protease cleavage site. Immunity 12, 391-398.
3. Asgian, J.L., James, K.E., Li, Z.Z., Carter, W., Barrett, A.J., Mikolajczyk, J., Salvesen, G.S. and Powers, J.C. (2002). Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases. J. Med. Chem. 45, 4958-4960.
4. Bates, I.R., Matharu, P., Ishiyama, N., Rochon, D., Wood, D.D., Polverini, E., Moscarello, M.A., Viner, N.J. and Harauz, G. (2000). Characterization of a recombinant murine 18.5-kDa myelin basic protein. Protein Expr. Purif. 20, 285-299.
5. Beck, H., Schwarz, G., Schroter, C.J., Deeg, M., Baier, D., Stevanovic, S., Weber, E., Driessen, C. and Kalbacher, H. (2001). Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur. J. Immunol. 31, 3726-3736.
6. Billson, J., Clark, J., Conway, S.P., Hart, T., Johnson, T., Langston, S.P., Ramjee, M., Quibell, M. and Scott, R.K. (1998). The design and synthesis of inhibitors of the cysteinyl protease, Der p I. Bioorg. Med. Chem. Lett. 8, 993-998.
7. Chen, J.M., Dando, P.M., Rawlings, N.D., Brown, M.A., Young, N.E., Stevens, R.A., Hewitt, E., Watts, C. and Barrett, A.J. (1997). Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J. Biol. Chem. 272, 8090-8098.
8. Chen, J.-M., Rawlings, N.D., Stevens, R.A.E. and Barrett, A.J. (1998). Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cystein endopeptidases. FEBS Lett. 441, 461-365.
9. Chen, J.M., Fortunato, M. and Barrett, A.J. (2000). Activation of human prolegumain by cleavage at a C-terminal asparagine residue. Biochem. J. 352, 327-334.
10. Chen, J.M., Fortunato, M., Stevens, R.A. and Barrett, A.J. (2001). Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol. Chem. 382, 777-783.
11. Choi, S.J., Reddy, S.V., Devlin, R.D., Menaa, C., Chung, H., Boyce, B.F. and Roodman, G.D. (1999). Identification of human asparaginyl endopeptidase (Legumain) as an inhibitor of osteoclast formation and bone resorption. J. Biol. Chem. 274, 27747-27753.
12. Choi, S.J., Kurihara, N., Oba, Y. and Roodman, G.D. (2001). Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. J. Bone Miner. Res. 16, 1804-1811.
13. CRC Handbook of Chemistry and Physics (1992). 73rd Edition, D.R. Lide, ed. (Boca Raton, USA: CRC Press, Inc.), pp. 8-40.
14. Dando, P.M., Fortunato, M., Smith, L., Knight, C.G., McKendrick, J.E. and Barrett, A.J. (1999). Pig kidney legumain: an asparaginyl endopeptidase with restricted specificity. Biochem. J. 339, 743-749.
15. Hewitt, E.W., Treumann, A., Morrice, N., Tatnell, P.J., Kay, J. and Watts, C. (1997). Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin: implications for T cell epitope generation. J. Immunol. 159, 4693-4699.
16. Kati, W.M., Sham, H.L., McCall, J.O., Montgomery, D.A., Wang, G.T., Rosenbrook, W., Miesbauer, L., Buko, A. and Norbeck, D.W. (1999). Inhibition of 3C protease from human rhinovirus strain 1B by peptidyl bromomethylketonehydrazides. Arch. Biochem. Biophys. 362, 363-375.
17. Krantz, A., Copp, L. J., Coles, P. J., Smith, R. A. and Heard, S. B. (1991). Peptidyl (acyloxy)methyl ketones and the quiescent affinity label concept: the departing group as a variable structural element in the design of inactivators of cysteine proteinases. Biochemistry 30, 4678-87.
18. Manoury, B., Hewitt, E.W., Morrice, N., Dando, P.M., Barrett, A.J. and Watts, C. (1998). An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396, 695-699.
19. Manoury, B., Gregory, W.F, Maizels, R.M. and Watts, C. (2001). Bm-CPI-2, a cystatin homolog secreted by the filarial parasite Brugia malayi, inhibits class II MHC-restricted antigen processing. Curr. Biol. 11, 447-451.
20. Manoury, B., Mazzeo, D., Fugger, L., Viner, N., Ponsford, M., Streeter, H., Mazza, G., Wraith, D.C. and Watts, C. (2002). Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nature Immunol. 3, 169-174.
21. Manoury, B., Mazzeo, D., Li, D.N., Billson, J., Loak, K., Benaroch, P. and Watts, C. (2003). Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone. Immunity 18, 489-498.
22. Morrison, J.F. and Walsh, C.T. (1988). The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-301.
23. Niestroj, A.J., Feussner, K., Heiser, U., Dando, P.M., Barrett, A., Gerhartz, B. and Demuth, H.U. (2002). Inhibition of mammalian legumain by Michael acceptors and AzaAsnhalomethylketones. Biol. Chem. 383, 1205-1214.
24. Riese, R.J., Wolf, P.R., Bromme, D., Natkin, L.R., Villadangos, J.A., Ploegh, H.L. and Chapman, H.A. (1996). Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 4, 357-366.
25. Thornberry, N.A., Peterson, E.P., Zhao, J.J., Howard, A.D., Griffin, P. R. and Chapman, K.T. (1994). Inactivation of interleukin-1β converting enzyme by peptide (acyloxy)methyl ketones. Biochemistry 33, 3934-3940.